EMITF Elbit Imaging

ELBIT IMAGING ANNOUNCES VOLUNTARY SEC DEREGISTRATION

ELBIT IMAGING ANNOUNCES VOLUNTARY SEC DEREGISTRATION

Tel Aviv, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, that its Board of Directors approved the filing of a Form 15F with the Securities and Exchange Commission ("SEC") to voluntarily deregister its ordinary shares under Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act"). The Company will file today the Form 15F. The Company's reporting obligations under the Exchange Act will be suspended immediately upon the filing of Form 15F and will terminate 90 days thereafter if there are no objections from the SEC.

Following the deregistration, the Company’s ordinary shares will continue to trade on the Tel Aviv Stock Exchange and, in addition, are traded on the over-the-counter (OTC) market in the U.S.

In deciding to voluntarily deregister its ordinary shares, the Company's Board of Directors considered several factors, including the low U.S. trading volume of the ordinary shares and the fact that the Company last raised proceeds in a public offering in the U.S. several years ago; the high public company costs in the U.S., including those associated with preparation and filing of the Company's periodic reports with the SEC, and the increased legal exposure that results from remaining a U.S. reporting company, which is also reflected in the increased cost of a D&O liability insurance policy for reporting companies in U.S.; the significant management time spent on U.S. regulatory compliance; and the fact that the Company's shares continue to trade on the Tel Aviv Stock Exchange, providing Company shareholders with a venue to continue trading their shares.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; and (ii) land plots in India which are designated for sale (and which were initially designated for residential projects).

For Further Information:

Company Contact

Ron Hadassi

CEO and Chairman of the Board of Directors

Tel:

Fax:

EN
08/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Elbit Imaging

 PRESS RELEASE

ELBIT IMAGING ANNOUNCES VOLUNTARY SEC DEREGISTRATION

ELBIT IMAGING ANNOUNCES VOLUNTARY SEC DEREGISTRATION Tel Aviv, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, that its Board of Directors approved the filing of a Form 15F with the Securities and Exchange Commission ("SEC") to voluntarily deregister its ordinary shares under Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act"). The Company will file today the Form 15F. The Company's reporting obligations under the Exchange Act will be suspended immediately upon the filing...

 PRESS RELEASE

ELBIT Imaging Announces Update Regarding the Agreement to Sell Its Hol...

ELBIT Imaging Announces Update Regarding the Agreement to Sell Its Holdings In the Project in Bangalore, India TEL AVIV, Israel, July 25, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated May 27, 2019, regarding an agreement (the "Agreement") signed by Elbit Plaza India Real Estate Holdings Limited (a subsidiary held by the Company (50%) and Plaza Centers N.V. (50%)) ("EPI"), for the sale of a 100% interest in a Special Purpose Vehicle which holds a site in Bangalore, India, to a local investor ...

 PRESS RELEASE

ELBIT IMAGING LTD. ANNOUNCES THAT INSIGHTEC RECEIVES FDA APPROVAL AND ...

ELBIT IMAGING LTD. ANNOUNCES THAT INSIGHTEC RECEIVES FDA APPROVAL AND CE MARK FOR EXABLATE NEURO WITH GE SIGNA PREMIER MRI SYSTEM Tel Aviv, Israel, July 10, 2019 (GLOBE NEWSWIRE) --  Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today that Insightec Ltd. ("Insightec") announced today FDA approval and CE mark for Exablate Neuro™ compatible with the SIGNA™ Premier MRI system from GE Healthcare. Exablate Neuro has FDA approval for the treatment of medication-refractory essential tremor and tremor-dominant Parkinson's disease and CE mark for the treatment...

 PRESS RELEASE

ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES FULL EXERCISE OF UN...

ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Tel Aviv, Israel, July 08, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press release dated June 27, 2019 that Gamida Cell Ltd. (Nasdaq: GMDA) (“Gamida”), an indirect shareholding of the Company announced that the underwriters of its recently closed underwritten public offering of 7,000,000 ordinary shares have exercised in full their option to purchase an additional 1,050,000 ordinary shares ...

 PRESS RELEASE

ELBIT IMAGING ANNOUNCES RECEIVING FIRST INTEREST PAYMENT UNDER THE VEN...

ELBIT IMAGING ANNOUNCES RECEIVING FIRST INTEREST PAYMENT UNDER THE VENDOR LOAN GIVEN TO THE RADISSON HOTEL PURCHASER Tel Aviv, Israel, July 03, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press releases dated December 18, 2017 and April 2, 2019 regarding the sale of its holdings in a SPV that holds the Radisson Hotel Complex in Bucharest, Romania (the "Agreement"), in which the Company has granted to the hotel's purchaser (the "Purchaser") a vendor loan of €8 million (the "Vendor Loan"), that the Purchaser ha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch